Trending: Roche's Alzheimer's Drug Fails in Late-Stage Trial
November 14 2022 - 10:53AM
Dow Jones News
10:23 a.m. ET -- Roche Holding AG is one of the most talked
about companies in the U.S. across all news items in the last 12
hours, according to Factiva data. Roche said its experimental
Alzheimer's drug failed to significantly slow cognitive decline in
long-awaited trials, the latest in a long line of setbacks for a
field that has seen little progress in decades. The drug, called
gantenerumab, slightly reduced cognitive decline in people with
early Alzheimer's compared with a placebo across two large and
lengthy trials, but the difference wasn't statistically
significant, Roche said Monday. Dow Jones & Co. owns Factiva.
(chris.wack@wsj.com)
(END) Dow Jones Newswires
November 14, 2022 10:38 ET (15:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2023 to Jul 2024